AMRX vs AZN

AMRX's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns about operational efficiency and profitability sustainability. The absence of an Altman Z-Score and a Debt/Equity ratio of 450.96 signal extreme leverage and potential distress risk, severely undermining financial stability. Despite strong revenue growth (11.5% YoY) and impressive earnings surprises (average +26.6% over last 4 quarters), the stock trades at a forward P/E of 10.12 but a trailing P/E of 53.77, suggesting overvaluation relative to current earnings. The lack of dividends, negative Price/Book, and bearish insider activity further erode investor confidence. The stock's 1-month decline of 19.5% reflects deteriorating market sentiment despite a strong 3-year return.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.